One of the largest ever clinical trials in children with Rolandic epilepsy, coordinated by the University of Liverpool, is launching on ‘Purple Day’, the family-focused epilepsy awareness day.
Researchers from the Clinical Trials Research Centre at the University of Liverpool have been involved with designing and coordinating the nationwide CASTLE trial, which is one of the only trials to compare antiepileptic drugs against active monitoring with no medication.
Rolandic epilepsy is the most common form of childhood epilepsy, affecting around 10,000 young people in the U.K. Seizures happen most often at night and affect children between the ages of 5 and 12 before tapering off in adolescence.
Treating epilepsy with drugs to reduce seizures has traditionally been the goal of medical treatment. However, the drugs used to treat epilepsy often slow down a child’s thinking and learning. Because children with Rolandic epilepsy ‘grow out’ of their seizures, doctors and parents often don’t know whether to treat children or not, and many families choose no medication.
The CASTLE research programme focuses on more than seizures, to consider the wider aspects of living with Rolandic epilepsy that are of importance to families, such as children’s learning, sleep, behaviour, self-esteem and mood. Families have been central to the research programme in guiding the best ways to measure health and quality of life for children.
The trial will compare two licensed drugs, comparing their effects to active monitoring with no medication. NICE guidelines recommend treatment with the standard epileptic drug carbamazepine which is very effective at preventing seizures but can have negative impacts on learning. A newer drug called levetiracetam might be just as effective but without impacts on learning but has not been evaluated in a rigorous clinical trial for Rolandic epilepsy.
Professor Catrin Tudur Smith from the Clinical Trials Research Centre, Department of Biostatistics at University of Liverpool, said: “The CASTLE trial has been designed to answer questions that are important to children with Rolandic epilepsy and includes a core outcome set that has been developed using approaches recommended by the COMET Initiative led by Professor Paula Williamson.
“The Clinical Trials Research Centre is coordinating the CASTLE trial which will recruit patients from at least 28 NHS Trusts that have already signed up to take part. Information from the trial will help clinicians, children and their families to make decisions about the treatment of Rolandic epilepsy.”
Professor Deb Pal from the Institute of Psychiatry, Psychology & Neuroscience at King’s, and co-leader of the trial, said: “For the first time in a major trial we are taking a very broad view of outcomes, looking beyond seizures to learning and a host of other issues that are important to young people and their parents. We hope the results will put to bed the notion of whether antiepileptic drugs cause more harm than good for some children with epilepsy, and help families decide the best course of action.”
Sleep behaviour intervention
A second key aim of the CASTLE trial is testing whether improving sleep can reduce seizures. The researchers have developed the world’s first online sleep behaviour intervention especially for epilepsy, which teaches parents how to encourage good sleep in their children. The trial will test how well the sleep intervention works both with and without medication for seizures.
Professor Paul Gringras from Evelina London Children’s Hospital, and co-leader of the trial, said: “Sleep and seizures are intimate bedfellows. There is a vicious cycle whereby seizures and medications can affect sleep, but broken or insufficient sleep can also increase likelihood of seizures. This sleep disruption has huge impact on whole families, with mothers of children with epilepsy rarely getting more than four hours a night. We are asking a simple but vital question – can improving a child’s sleep reduce their seizures and improve their and their parents’ well-being?”
Source: University of Liverpool